Firefly Luciferase LNCaP Cell line

Products from BPS Bioscience require a minimum order value above 400€

Application: Use as an internal control in co-culture killing assaysIn vitro and in vivo bioluminescence imaging

Background: LNCaP is a human prostate carcinoma cell line isolated from the lymph node of a patient with metastatic prostate carcinoma. In contrary to many human cell lines derived from advanced prostate cancer patients, which are androgen-independent for growth and do not respond to  dihydrotestosterone (DHT), the LNCaP cell line responds to DHT in vitro  and is androgen-dependent for growth in vivo, making it one of the very few cell lines allowing the study of hormone-related treatments in xenograft models of prostate cancer. The presence of the luciferase reporter allows for easy assay readouts as luciferase activity is proportional to the number of cells.

Description: Firefly Luciferase LNCaP Cell Line is a human prostate carcinoma cell line engineered to express Firefly luciferase driven by a CMV promoter. This cell line was generated by transduction with Firefly Luciferase Lentivirus (#79692-P). 

Host Cell Line: LNCaP

Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.

Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.

Supplied As: Each vial contains >1 x 10⁶ cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)

Warnings: Avoid freeze/thaw cycles

Biosafety Level: BSL-1

• SKU: BPS82788
• Manufacturer: BPS Bioscience
• Manufacturer SKU: 82788
• Package Unit: 2 Vials
• Quantity Unit: PAK